CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
Intest Res. 2019;17(3):340-348.   Published online May 31, 2019
DOI: https://doi.org/10.5217/ir.2019.00012

Excel Download

Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Intestinal Research. 2019;17(3):340-348   Crossref logo
Link1 Link2 Link3

Ustekinumab success in refractory Crohn’s disease
Springer Healthcare News. 2012;1(1):   Crossref logo
Link1 Link2 Link3

Vedolizumab and ustekinumab cost effective in Crohn's disease
PharmacoEconomics & Outcomes News. 2018;802(1):34-34   Crossref logo
Link1 Link2 Link3

Demyelination in a patient receiving ustekinumab for refractory Crohn's disease: Figure 1
Journal of Crohn's and Colitis. 2014;8(9):1138-1139   Crossref logo
Link1

Refractory Pyoderma Gangrenosum in a Patient With Crohn’s Disease: Complete Response to Ustekinumab
Journal of Crohn's and Colitis. 2018;13(6):812-813   Crossref logo
Link1

Management of Paediatric Patients With Medically Refractory Crohn’s Disease Using Ustekinumab: A Multi-Centred Cohort Study
Journal of Crohn's and Colitis. 2018;13(5):578-584   Crossref logo
Link1

An Analysis of Social Media Use Surrounding the Approval of Ustekinumab (Stelara) for the Treatment of Crohn's Disease
Gastroenterology. 2017;152(5):S801   Crossref logo
Link1 Link2

Sa1211 Assessment of Sleep Impairment in Patients With Crohn's Disease: Results From the Ustekinumab Certifi Study
Gastroenterology. 2013;144(5):S-231   Crossref logo
Link1 Link2

Ustekinumab shows promise in the treatment of refractory Crohn's disease
Nature Reviews Gastroenterology & Hepatology. 2012;9(12):690-690   Crossref logo
Link1 Link2 Link3

Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience
Alimentary Pharmacology & Therapeutics. 2017;45(10):1374-1375   Crossref logo
Link1 Link2